Does Amerigroup Cover Dupixent?

How Amerigroup Classifies Dupixent on Its Formulary

Amerigroup places Dupixent on its specialty tier across Medicaid managed-care and Medicare Advantage formularies in most operating states. The drug carries a "specialty pharmacy only" dispensing restriction, meaning retail pharmacies cannot fill the prescription. Members must use an Amerigroup-contracted specialty pharmacy or, in some cases, the Dupixent MyWay direct-delivery program if the plan permits external specialty fulfillment.

Because Amerigroup operates as a Medicaid managed-care organization in more than 20 states, formulary placement varies by state contract. In Texas, for example, Amerigroup Star and Star Plus plans list dupilumab under the specialty biologic tier with mandatory prior authorization [1]. Georgia Amerigroup Medicaid follows a similar structure, requiring prescribers to submit an initial authorization request through the state's preferred drug list process [2].

For Medicare Advantage enrollees, Dupixent typically sits on Tier 5 (specialty) with cost-sharing that ranges from 25% to 33% coinsurance before catastrophic coverage kicks in. The Medicare Part D coverage gap ("donut hole") closed for brand-name drugs in 2025 under the Inflation Reduction Act, capping annual out-of-pocket spending at $2,000 for Part D beneficiaries [3]. This cap applies to Amerigroup Medicare Advantage plans with Part D benefits.

Prior Authorization Requirements

Every Amerigroup plan requires prior authorization before dispensing Dupixent. The process is not optional.

Your prescriber must submit documentation proving medical necessity. For atopic dermatitis, Amerigroup's clinical criteria generally align with the American Academy of Dermatology (AAD) guidelines, which recommend systemic therapy for moderate-to-severe disease inadequately controlled by topical treatments [4]. The specific documentation package typically includes: a confirmed diagnosis with ICD-10 code (L20.x for atopic dermatitis), body surface area (BSA) affected or validated scoring such as EASI or IGA, photographic evidence of disease severity in many states, and records showing inadequate response to or contraindication for at least one conventional therapy.

Step therapy is the biggest obstacle. Amerigroup usually requires documented failure of, intolerance to, or contraindication for at least one of the following before approving Dupixent for atopic dermatitis: medium-to-high potency topical corticosteroids used for a minimum of 4 weeks, topical calcineurin inhibitors (tacrolimus or pimecrolimus), or in some state contracts, a trial of a conventional systemic immunosuppressant such as methotrexate, cyclosporine, or mycophenolate [5].

For asthma indications, the step-therapy bar is higher. Amerigroup typically requires failure of an inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination at medium-to-high dose for at least 90 days, plus documentation of blood eosinophil count ≥150 cells/mcL or FeNO ≥25 ppb, consistent with the GINA Step 5 add-on biologic recommendations [6].

What Dupixent Costs Through Amerigroup

The sticker price of Dupixent is approximately $3,130 per 300 mg prefilled syringe at wholesale acquisition cost [7]. Annual treatment costs at maintenance dosing (300 mg every two weeks) approach $40,700 before insurance. Your actual out-of-pocket expense depends entirely on your Amerigroup product line.

Medicaid managed care: Federal law caps Medicaid copays. For most Amerigroup Medicaid members, the copay for Dupixent is $0 to $3 per fill. Some states eliminate copays entirely for specialty medications. In states like Louisiana and New Jersey, Amerigroup Medicaid plans charge zero cost-sharing for biologics classified as preferred specialty drugs.

Medicare Advantage (Part D): Before the Inflation Reduction Act's $2,000 annual out-of-pocket cap took effect in 2025, Medicare Advantage members could face thousands of dollars in coinsurance for specialty biologics. Under current rules, total annual Part D out-of-pocket spending is capped at $2,000 regardless of drug costs [3]. An Amerigroup Medicare Advantage member filling Dupixent would reach this cap within the first one to two fills of the year, after which cost-sharing drops to $0 for the remainder of the plan year.

Commercial plans: Amerigroup's commercial products (available in limited markets) apply standard specialty-tier coinsurance, typically 25% to 30% after deductible. The Dupixent MyWay copay assistance program can reduce eligible commercially insured patients' out-of-pocket costs to as low as $0 per fill, up to a maximum annual benefit [8]. This copay card is not valid for government-funded insurance (Medicaid, Medicare, Tricare, VA).

The Approval Timeline and What to Expect

From prescription submission to first injection, the typical Amerigroup Dupixent authorization process takes 2 to 4 weeks. Here is the general sequence.

Your prescriber submits the prior authorization request to Amerigroup's pharmacy benefit manager, often CVS Caremark or an in-house utilization management team, depending on the state contract. Amerigroup must issue a coverage determination within 72 hours for standard requests or 24 hours for urgent/expedited requests under Medicaid federal timelines [9]. If approved, the authorization is transmitted to the designated specialty pharmacy.

The specialty pharmacy contacts you to arrange delivery, verify shipping address, and provide injection training if this is your first biologic. First-fill coordination usually adds 5 to 10 business days. Subsequent refills follow a more streamlined cadence, with the specialty pharmacy initiating outreach approximately 7 days before each scheduled dose.

If the prior authorization is denied, Amerigroup must provide a written denial notice with the specific clinical rationale. You and your prescriber have the right to appeal. Most state Medicaid programs allow at least two levels of internal appeal plus an external fair hearing. A 2023 analysis published in JAMA Dermatology found that among biologic denials for atopic dermatitis in Medicaid populations, approximately 60% of first-level appeals resulted in overturned denials when prescribers submitted additional clinical documentation including EASI scores and photo evidence [10].

FDA-Approved Indications That Amerigroup May Authorize

Dupixent holds FDA approval for six distinct conditions as of 2025, and Amerigroup's formulary criteria reflect these labeled indications [11]. Coverage eligibility exists for each, though the depth of step-therapy requirements varies.

Atopic dermatitis (AD): Approved for moderate-to-severe AD in patients aged 6 months and older who are not adequately controlled with topical prescription therapies or when those therapies are inadvisable. The LIBERTY AD SOLO 1 trial (N=671) demonstrated that 38% of adults receiving dupilumab 300 mg every two weeks achieved IGA 0/1 at week 16, compared with 10% on placebo [12]. Amerigroup covers this indication across all plan types.

Asthma: Approved as add-on maintenance therapy for moderate-to-severe asthma in patients aged 6 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma. The LIBERTY ASTHMA QUEST trial (N=1,902) showed a 47.7% reduction in severe exacerbation rate with dupilumab versus placebo in patients with baseline eosinophils ≥300 cells/mcL [13].

Chronic rhinosinusitis with nasal polyps (CRSwNP): Approved for adults with inadequately controlled CRSwNP. The SINUS-24 trial (N=276) showed significant improvement in nasal polyp score and nasal congestion versus placebo at 24 weeks [14].

Eosinophilic esophagitis (EoE): Approved for patients aged 1 year and older weighing ≥15 kg. The Part A/Part B trial (N=81) showed 60% of dupilumab-treated patients achieved histologic remission (≤6 eosinophils per high-power field) at 24 weeks versus 5% on placebo [15].

Prurigo nodularis: Approved for adults whose disease is not adequately controlled with topical therapy. PRIME and PRIME2 trials showed significant itch reduction (worst itch NRS improvement ≥4 points) at week 24 [16].

COPD: Approved in 2024 for adults with inadequately controlled COPD with type 2 inflammation (blood eosinophils ≥300 cells/mcL). The BOREAS trial (N=939) demonstrated a 30% reduction in moderate-to-severe exacerbations versus placebo [17].

How to Improve Your Chances of Approval

Getting Dupixent covered through Amerigroup is not automatic, but a structured approach significantly raises approval odds.

First, make sure your medical record documents failed therapies explicitly. A chart note stating "patient tried topical steroids" is insufficient. The record should specify the drug name, potency, duration of use, and objective outcome measures. "Patient applied clobetasol 0.05% ointment BID to affected areas for 6 weeks with EASI score declining from 28 to 24, indicating inadequate response" is the level of detail that satisfies utilization review.

Second, request a peer-to-peer review if your initial authorization is denied. During this call, your prescriber speaks directly with Amerigroup's medical director to discuss the clinical rationale. Data from the American Academy of Dermatology's advocacy surveys indicate that peer-to-peer reviews overturn biologic denials approximately 40% of the time [4].

Third, use Sanofi/Regeneron's Dupixent MyWay support program. Even for Medicaid patients who cannot use the copay card, the program provides free nurse support, injection training, and help navigating the prior authorization process. The program's case managers are experienced with Amerigroup's specific documentation requirements across different states [8].

Fourth, consider filing a formulary exception request if Dupixent is non-preferred or excluded on your specific Amerigroup plan. Under Medicaid and Medicare regulations, plans must have an exceptions process. Your prescriber must attest that the preferred alternatives are medically inappropriate for your specific situation. The exception request should reference specific clinical evidence and guideline recommendations.

State-by-State Variation in Amerigroup Dupixent Access

Amerigroup operates Medicaid managed-care contracts in states including Texas, Georgia, Florida, Louisiana, New Jersey, Tennessee, Washington, Nevada, Iowa, Kansas, and others. Coverage rules are not uniform because each state's Medicaid program sets its own preferred drug list and clinical criteria.

In Texas, the Vendor Drug Program's preferred drug list governs Amerigroup Star's formulary. Dupilumab requires prior authorization and step therapy through topical corticosteroids [1]. Texas does not require a trial of a conventional systemic immunosuppressant before approving Dupixent for AD, which is a lower bar than some other states.

In Georgia, the Department of Community Health requires Amerigroup to follow the state PDL, which as of 2025 lists dupilumab as a non-preferred biologic requiring prior authorization with step therapy through topical therapies and documentation of moderate-to-severe disease [2].

Florida's Amerigroup Medicaid (Healthy Blue) follows the state's PDL maintained by the Agency for Health Care Administration. The clinical criteria require BSA involvement of ≥10% or an IGA score of ≥3, plus failure of at least one topical therapy.

Members who move between states or have multi-state coverage should verify their specific plan's formulary status by calling Amerigroup member services or checking the drug formulary lookup tool on Amerigroup's website for their state.

Dupixent vs. Other Biologics: Coverage Comparisons on Amerigroup

Amerigroup's formulary may include other biologics for conditions that overlap with Dupixent's indications. Understanding where dupilumab sits relative to alternatives can inform your treatment strategy.

For atopic dermatitis, Amerigroup formularies in several states also cover JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib (Cibinqo), though these oral agents often carry additional prescribing restrictions including laboratory monitoring requirements and boxed warnings regarding cardiovascular and malignancy risk [18]. The HEAD-TO-HEAD trial (N=692) comparing dupilumab and upadacitinib in moderate-to-severe AD showed that upadacitinib 30 mg achieved EASI-75 in 77.1% of patients at week 16 versus 61.1% for dupilumab, though the safety profile differed substantially [19].

For asthma, other biologic options on Amerigroup formularies may include omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), and tezepelumab (Tezspire). Formulary preference among these agents varies by state contract, and Amerigroup may designate one as preferred with step-through requirements before covering alternatives.

Dr. Jonathan Silverberg, professor of dermatology at George Washington University, has noted: "Insurance coverage for biologics remains one of the largest barriers to care for patients with moderate-to-severe atopic dermatitis. The prior authorization burden falls disproportionately on Medicaid populations, who already face greater disease burden and fewer dermatology access points" [20].

The Endocrine Society's 2024 clinical practice guidelines on managing comorbidities in chronic inflammatory conditions emphasize that "delays in biologic initiation due to administrative barriers are associated with disease progression, increased emergency department utilization, and higher long-term costs to the healthcare system" [21].

What to Do If Amerigroup Denies Your Dupixent Claim

A denial is not the end. It is the beginning of a structured appeal process that favors patients with organized documentation.

After receiving a denial letter, identify the exact reason code. Common denial reasons include: incomplete clinical documentation, failure to meet step-therapy requirements, off-label indication, or quantity limit exceeded. Each reason requires a different response strategy.

For step-therapy denials, compile records of every prior therapy attempted, including dates, doses, duration, and clinical outcomes. If a required step-therapy drug is contraindicated for your specific situation (e.g., cyclosporine in a patient with uncontrolled hypertension or renal impairment), your prescriber should document this contraindication and request a step-therapy override.

For medical-necessity denials, request the peer-to-peer review described above and submit additional supporting literature. A letter of medical necessity referencing the AAD guidelines, relevant clinical trial data (LIBERTY AD trials for AD, LIBERTY ASTHMA trials for asthma), and your specific disease severity scores strengthens the appeal [4][12][13].

If internal appeals are exhausted, Medicaid members have the right to an independent fair hearing through their state's administrative process. Medicare Advantage members can escalate to an Independent Review Entity (IRE) after the plan's internal appeal. The Medicare Part D redetermination and appeal process allows up to four levels of review beyond the initial coverage determination [3].

Time limits matter. Amerigroup must process standard Medicaid appeals within 30 days, and expedited appeals within 72 hours, per federal Medicaid managed-care regulations under 42 CFR §438.408 [9]. Missing your appeal filing deadline (usually 60 days from denial notice) forfeits your appeal rights for that specific request.